Xtant Medical reports an 85.30 percent short-interest drop for Xtant Medical stock

Published on 10/15/2026 at 13:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Short interest fell 85.30 percent to 268,742 shares on September 15, 2026. Xtant Medical stock trades at EUR 0.29 on October 15, 2026.

Operating pressure and ownership data

Short interest fell 85.30 percent to 268,742 shares on September 15, 2026.
Second-quarter revenue declined from USD 35.41 million to USD 23.03 million year over year.
Xtant Medical stock traded at EUR 0.29 at 1:02 p.m. CEST at Lang & Schwarz on October 15, 2026.
The company had a USD 44.7 million market capitalization as of October 14, 2026.

XTNT, US98420P3082, Illustration mit AI erstellt.

Xtant Medical (US98420P3082) reported an 85.30 percent decline in short interest to 268,742 shares as of September 15, 2026. The figure was published by MarketBeat on September 25, 2026, alongside a report that two analysts held Buy ratings and an average USD 1.00 price target. Xtant Medical stock was trading at EUR 0.29 at Lang & Schwarz on October 15, 2026 at 1:02 p.m. CEST.

Short interest resets the investor context

The short-interest change is the clearest recent market statistic attached to Xtant Medical. MarketBeat said short interest fell from 1.83 million shares at the end of August to 268,742 shares on September 15, 2026, while short interest represented 0.20 percent of shares outstanding.

The same MarketBeat report placed the average analyst target at USD 1.00 and cited Loop Capital as setting that target on September 2, 2026. The target is a separate U.S. dollar valuation reference and does not replace the euro quote used for this article.

What does the latest loss mean?

The operating figures remain the central counterweight. In its second-quarter 2026 filing dated August 11, 2026, Xtant Medical reported revenue of USD 23.03 million, down from USD 35.41 million in the second quarter of 2025, and a net loss of USD 9.41 million versus net income of USD 3.55 million. MarketWatch reported that the company also reduced its 2026 revenue guidance to USD 99 million to USD 103 million from USD 101 million to USD 105 million.

Three dated operating markers

On December 12, 2025, Xtant Medical highlighted the commercial launch of its next-generation nanOss Strata synthetic bone graft in its investor materials, alongside its regenerative medicine and spinal implant portfolio, according to the company's Xtant Medical investor page. On August 11, 2026, the company reported second-quarter revenue of USD 23.03 million. On September 25, 2026, MarketBeat reported the 85.30 percent short-interest reduction.

Cash and valuation frame the stock

Xtant Medical reported USD 9.87 million in cash and cash equivalents as of June 30, 2026, while operating cash flow for the first half of 2026 was negative USD 7.31 million. The finance profile identified the company as a healthcare medical-device business with 151 employees, and the market capitalization was USD 44.7 million as of October 14, 2026.

Stock quote and investor reference

The stock was trading at EUR 0.29 at Lang & Schwarz on October 15, 2026 at 1:02 p.m. CEST. The primary listing is on the NYSE American under ticker XTNT, where the latest structured quote was USD 0.32 at October 14, 2026 at 4:00 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Xtant Medical stock.